JP2021527129A5 - - Google Patents

Info

Publication number
JP2021527129A5
JP2021527129A5 JP2021518057A JP2021518057A JP2021527129A5 JP 2021527129 A5 JP2021527129 A5 JP 2021527129A5 JP 2021518057 A JP2021518057 A JP 2021518057A JP 2021518057 A JP2021518057 A JP 2021518057A JP 2021527129 A5 JP2021527129 A5 JP 2021527129A5
Authority
JP
Japan
Prior art keywords
subject
product according
pharmaceutical product
administration
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021518057A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021527129A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/036139 external-priority patent/WO2019237054A1/en
Publication of JP2021527129A publication Critical patent/JP2021527129A/ja
Publication of JP2021527129A5 publication Critical patent/JP2021527129A5/ja
Pending legal-status Critical Current

Links

JP2021518057A 2018-06-08 2019-06-07 カルシフィラキシスを予防または治療するための方法および組成物 Pending JP2021527129A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862682794P 2018-06-08 2018-06-08
US62/682,794 2018-06-08
PCT/US2019/036139 WO2019237054A1 (en) 2018-06-08 2019-06-07 Methods and compositions for preventing or treating calciphylaxis

Publications (2)

Publication Number Publication Date
JP2021527129A JP2021527129A (ja) 2021-10-11
JP2021527129A5 true JP2021527129A5 (enExample) 2022-06-10

Family

ID=68763971

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021518057A Pending JP2021527129A (ja) 2018-06-08 2019-06-07 カルシフィラキシスを予防または治療するための方法および組成物

Country Status (11)

Country Link
US (7) US10736858B2 (enExample)
EP (1) EP3801478A4 (enExample)
JP (1) JP2021527129A (enExample)
KR (1) KR20210018422A (enExample)
CN (1) CN112955131A (enExample)
AU (1) AU2019282421B2 (enExample)
CA (1) CA3102979A1 (enExample)
IL (1) IL279246B2 (enExample)
MX (2) MX2020013301A (enExample)
SG (1) SG11202012055PA (enExample)
WO (1) WO2019237054A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019237054A1 (en) 2018-06-08 2019-12-12 Epizon Pharma, Inc. Methods and compositions for preventing or treating calciphylaxis
IL279245B2 (en) 2018-06-08 2024-03-01 Epizon Pharma Inc Compositions comprising menaquinone-7 (mk-7) and/or menquinol for prophylaxis of tissue calcification
WO2020055678A1 (en) 2018-09-12 2020-03-19 Epizon Pharma, Inc. Menaquinol compositions and methods of treatment
US20220079891A1 (en) * 2019-01-04 2022-03-17 L. J. Schurgers Combination therapy of phosphate binders and vitamin k
CN112691058A (zh) * 2020-12-31 2021-04-23 玉溪健坤生物药业有限公司 一种含还原型维生素k2的牙膏及其制备方法
CN114748486A (zh) * 2022-03-25 2022-07-15 南京盛德生物科技研究院有限公司 一种含有维生素k2改善心血管钙化的药物组合物及其制备方法与应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050176778A1 (en) 2001-08-03 2005-08-11 Vitak Bv Isoprenyl derivatives and their use in the title treatment and prevention of osteoporosis and cardiovascular calcification
WO2005030190A1 (en) 2003-09-26 2005-04-07 Natural Asa Natural menaquinone 7 compositions
SI1728507T1 (sl) 2005-06-03 2011-07-29 Nattopharma Asa Uporaba vitamina K za reverziranje kalcifikacije krvnih Ĺľil
US20070208086A1 (en) 2006-02-15 2007-09-06 The Regents Of The University Of California Ubiquinone analogs and methods of use
EP2046312B1 (en) * 2006-07-14 2020-02-19 Kaydence Pharma AS Pharmaceutical and nutraceutical products comprising vitamin k2
GB0817528D0 (en) 2008-09-24 2008-10-29 Syntavit As Process
WO2012059942A2 (en) * 2010-11-01 2012-05-10 Viridis Biopharma Pvt. Ltd Dynamic balancing of autonomic nervous system through vitamin mk-7
GB201203705D0 (en) 2012-03-02 2012-04-18 Kappa Bioscience As Prodrugs
ES2869202T3 (es) 2012-06-18 2021-10-25 Fresenius Kabi Deutschland Gmbh Sistema de cánula para vía para la punción de vías centrales de acceso subcutáneo
WO2014191466A1 (en) 2013-05-28 2014-12-04 Nattopharma Asa Menaquinone supplementation and vascular health
GB201314245D0 (en) 2013-08-08 2013-09-25 Kappa Bioscience As Provitamins
EP2868658B1 (en) 2013-11-01 2018-05-02 Dilip Mehta Method of preparation of stereospecific quinone derivatives
WO2016131993A2 (en) * 2015-02-20 2016-08-25 Vitak B.V. Vitamin k and capillary function
MX2017011934A (es) 2015-03-20 2018-02-09 Gnosis Spa Formas solidas de menaquinoles.
CN206387961U (zh) 2016-12-30 2017-08-08 孙淑芬 头戴显示设备
IT201700085412A1 (it) 2017-07-26 2019-01-26 Pharmanutra S P A Composizione per uso nella prevenzione e nel trattamento di patologie dell'apparato cardiovascolare
US10368858B1 (en) 2018-01-25 2019-08-06 Ring Orthopedics, Inc. Suture passer
US11407704B2 (en) 2018-04-06 2022-08-09 Siec Badawcza Lukasiewicz-Instytut Chemii Przemyslowej Imienia Profesora Ignacego Moscickiego Process of vitamin K2 derivatives preparation
WO2019237054A1 (en) 2018-06-08 2019-12-12 Epizon Pharma, Inc. Methods and compositions for preventing or treating calciphylaxis
IL279245B2 (en) 2018-06-08 2024-03-01 Epizon Pharma Inc Compositions comprising menaquinone-7 (mk-7) and/or menquinol for prophylaxis of tissue calcification
WO2020055678A1 (en) 2018-09-12 2020-03-19 Epizon Pharma, Inc. Menaquinol compositions and methods of treatment

Similar Documents

Publication Publication Date Title
JP2021527129A5 (enExample)
JP2021527128A5 (enExample)
Boojar et al. Overview of Silibinin anti-tumor effects
Andújar et al. Shikonin promotes intestinal wound healing in vitro via induction of TGF-β release in IEC-18 cells
CN101217952B (zh) 用于预防心血管事件发病的组合物
JP2022554020A5 (enExample)
JP2023022079A (ja) アルカリ性化剤による血液浄化
CN113038940A (zh) 用于预防或治疗组织钙化的方法和组合物
KR20240040767A (ko) His 저감반응자의 치료
Kim et al. A prospective multi-center trial of Escherichia coli extract for the prophylactic treatment of patients with chronically recurrent cystitis
JP2018516931A5 (enExample)
JP6207560B2 (ja) 膵炎を治療するためのゲムカベンおよび誘導体
JP2019513802A (ja) 組み合わせ組成物およびその使用方法
RU2447913C1 (ru) Способ лечения местнораспространенного рака молочной железы с опухолевыми изъязвлениями кожи
Yahya et al. Old drug with new milestone: chloroquine and hydroxychloroquine in SARS-COV-2 (COVID-19) with multifaceted effects in other diseases
JP6184960B2 (ja) メラトニンの新規用途
CN105434459A (zh) 一种治疗溃疡的西药配方及其制备工艺
EP3969110A1 (en) Compositions comprising 15-hepe and/or 15-hetre and methods of treating or preventing cardiometabolic disease, metabolic syndrome, and/or related diseases
ROCHA et al. Functional nutrition in postoperative plastic surgery: focus on seroma and fibrosis prevention
HINT FICA: Taking a Spiritual History
KR20050090374A (ko) 위식도 역류 치료에서의 테나토프라졸의 용도
CN101766618A (zh) 匹伐他汀钙的新用途以及针对新用途的药物
WO2017180259A1 (en) Methods for treating nsaid-induced cardiovascular, cerebrovascular, or renovascular adverse events
JPWO2006011495A1 (ja) 高コレステロール血症及び/又は高トリグリセリド血症治療剤
AU2015202580B2 (en) Gemcabene and derivatives for treating pancreatitis